Cargando…

Alternative mechanisms of miR-34a regulation in cancer

MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge t...

Descripción completa

Detalles Bibliográficos
Autores principales: Slabáková, Eva, Culig, Zoran, Remšík, Ján, Souček, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682661/
https://www.ncbi.nlm.nih.gov/pubmed/29022903
http://dx.doi.org/10.1038/cddis.2017.495
_version_ 1783278136139448320
author Slabáková, Eva
Culig, Zoran
Remšík, Ján
Souček, Karel
author_facet Slabáková, Eva
Culig, Zoran
Remšík, Ján
Souček, Karel
author_sort Slabáková, Eva
collection PubMed
description MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMT or inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function.
format Online
Article
Text
id pubmed-5682661
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-56826612017-11-16 Alternative mechanisms of miR-34a regulation in cancer Slabáková, Eva Culig, Zoran Remšík, Ján Souček, Karel Cell Death Dis Review MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMT or inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function. Nature Publishing Group 2017-10-12 /pmc/articles/PMC5682661/ /pubmed/29022903 http://dx.doi.org/10.1038/cddis.2017.495 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Review
Slabáková, Eva
Culig, Zoran
Remšík, Ján
Souček, Karel
Alternative mechanisms of miR-34a regulation in cancer
title Alternative mechanisms of miR-34a regulation in cancer
title_full Alternative mechanisms of miR-34a regulation in cancer
title_fullStr Alternative mechanisms of miR-34a regulation in cancer
title_full_unstemmed Alternative mechanisms of miR-34a regulation in cancer
title_short Alternative mechanisms of miR-34a regulation in cancer
title_sort alternative mechanisms of mir-34a regulation in cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5682661/
https://www.ncbi.nlm.nih.gov/pubmed/29022903
http://dx.doi.org/10.1038/cddis.2017.495
work_keys_str_mv AT slabakovaeva alternativemechanismsofmir34aregulationincancer
AT culigzoran alternativemechanismsofmir34aregulationincancer
AT remsikjan alternativemechanismsofmir34aregulationincancer
AT soucekkarel alternativemechanismsofmir34aregulationincancer